Showing results (331-340 of 345) with videos related to
Sort By:
Pageof 35
British Journal of Cancer|September 23, 2020
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neckHye Ryun Kim, Han Na Kang, Mi Ran Yun, et al.The Lancet. Oncology|October 8, 2019
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 studyMyung-Ju Ahn, Ji-Youn Han, Ki Hyeong Lee, et al.Cancer Research and Treatment|September 5, 2018
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13Kwai Han Yoo, Su Jin Lee, Jinhyun Cho, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 25, 2023
Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T CellsSe-Hoon Lee, Yeongmin Kim, Bu-Nam Jeon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2015
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04Jin Seok Ahn, Yong Chan Ahn, Joo-Hang Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III StudyLin Shen, Ken Kato, Sung-Bae Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2023
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)Sehhoon Park, Tae Min Kim, Ji-Youn Han, et al.International Journal of Oncology|November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart reviewWilliam K Oh, David McDermott, Camillo Porta, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2021
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase InhibitorsByoung Chul Cho, Ji-Youn Han, Sang-We Kim, et al.Oncotarget|October 14, 2015
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinomaHyo Song Kim, Sung-Moo Kim, Hyunki Kim, et al.Pageof 35